Korea Concludes 12th Global Bio Conference with 5,600 Participants
News related to:Ministry of Food and Drug Safety of Korea · 2 min read
The Ministry of Food and Drug Safety of Korea has concluded its 12th edition of the Global Bio Conference (GBC), held from August 26 to 28 in Seoul. This year’s event, themed “The Great Leap in Bio, Accelerating Innovation,” attracted approximately 5,600 participants from 19 countries, including regulatory authorities, pharmaceutical and biotech industry professionals, and academic experts.
The conference served as a platform for sharing the latest advancements in biopharmaceutical technology and regulatory policies. Over the three-day event, 75 biopharmaceutical experts presented on topics ranging from vaccines to advanced biopharmaceuticals. The discussions covered the regulatory response strategies to emerging technologies such as artificial intelligence and advanced biopharmaceuticals, aligning with the evolving biopharmaceutical development environment.
In addition to the presentations, GBC featured specific forums dedicated to vaccines, recombinant protein products, and advanced biopharmaceuticals. These forums shared the latest research and development trends, along with approval and review case studies, aimed at fostering a regulatory environment that accelerates the development of innovative biopharmaceuticals.
The conference also focused on strengthening international regulatory cooperation. The Ministry of Food and Drug Safety of Korea organized 23 meetings, including five regulatory cooperation meetings, with overseas regulators and industry experts. These interactions included discussions on the approval and review systems of recombinant protein products, as well as joint review cases, particularly for advanced biopharmaceuticals. For instance, the conference included a joint workshop with Japan’s regulatory authority, focusing on the review cases of advanced biopharmaceuticals, including the world’s first approved induced pluripotent stem cell (iPSC) therapy.
Notably, the Ministry of Food and Drug Safety of Korea also engaged in bilateral meetings with the Indonesian Food and Drug Authority (BPOM) to discuss the stable supply of source plasma. This collaboration was built on the foundation of regulatory trust and aimed to support the registration of Korea as a reference country for Indonesia, with ongoing discussions to implement this agreement.
The GBC marked a significant step forward in regulatory innovation in the biopharmaceutical field. The Ministry of Food and Drug Safety of Korea stated its intention to continue supporting Korean companies as they expand into the global market. By fostering a network of cooperation among regulatory authorities and industry experts, the Ministry aims to position South Korea as a leader in global biopharmaceutical regulation and industrial innovation.